These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 18942400

  • 1. [Role of hormonal profile in adjusting therapy for prostate cancer].
    Granov AM, Molchanov OE, Karelin MI.
    Vopr Onkol; 2008; 54(4):457-62. PubMed ID: 18942400
    [Abstract] [Full Text] [Related]

  • 2. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N, Klotz L, Crook J, Goldenberg SL.
    Cancer; 2007 Mar 01; 109(5):858-67. PubMed ID: 17265527
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL, FinnProstate Group.
    J Urol; 2008 Sep 01; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.
    BJU Int; 2009 Nov 01; 104(9):1208-14. PubMed ID: 19388987
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
    Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2009 Jul 15; 74(4):1143-9. PubMed ID: 19117691
    [Abstract] [Full Text] [Related]

  • 12. Pretreatment hormone levels in prostatic cancer.
    Haapiainen R, Rannikko S, Alfthan O, Adlercreutz H.
    Scand J Urol Nephrol Suppl; 1988 Jul 15; 110():137-43. PubMed ID: 3187401
    [Abstract] [Full Text] [Related]

  • 13. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML, Keane TE, Evans CP.
    Can J Urol; 2007 Dec 15; 14 Suppl 1():10-8. PubMed ID: 18163939
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.